Biopharma’s buyout year ends with a bang
A recent buying spree swells 2021's meagre M&A tally, but the Pfizer-Arena deal could crystallise antitrust concerns.
CSL pays $11.7bn for new blood
The biggest biopharma deal of the year is also the biggest the Australian group has ever done.
Centessa claims a place in the antitrypsin deficiency pipeline
But investors will need more convincing; and others are more advanced, with Arrowhead and Inhibrx ones to watch.
Covid-19 vaccine developers remind the world that setbacks happen
As Biontech and Pfizer’s Covid-19 vaccine gets a positive US vote, delays for Sanofi, Glaxo and CSL show that top-speed drug development is the exception.
